EU now turns to BioNTech/Pfizer

Brussels, April 14: The EU is turning more heavily to BioNTech/Pfizer to make up for suspended Johnson & Johnson vaccine doses and for longer-term needs to fight the mutating Coronavirus, its chief Ursula von der Leyen said Wednesday.

BioNTech/Pfizer is bringing forward delivery of 50 million doses to the second quarter, starting this month, to help make up for the shortfall of the J&J jabs that were meant to start rolling out, she said in a televised statement.